CJC-1295 (without DAC) and LGD-4033 Interaction

Monitor
Mechanism-based 51% confidence

CJC-1295 (without DAC) and LGD-4033 have an interaction requiring monitoring for interaction with 51% confidence. Both CJC-1295 (without DAC) and LGD-4033 can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. These compounds primarily affect different organ systems.

Compound Profiles

CJC-1295 (without DAC)

Short-Acting Growth Hormone Releasing Hormone Analog

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Half-life: 30 minutes - 2 hours Typical dose: 100-300mcg per injection growth hormone, weight loss
ghrh receptor carcinogenic riskestrogenicinsulin disruptingteratogenic
View full profile

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Half-life: ~24-36 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
GI Tract
low
Pituitary
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (CJC-1295 (without DAC), LGD-4033). Monitor accordingly.
2x 2 estrogenic compounds (CJC-1295 (without DAC), LGD-4033). Combined estrogen elevation — monitor E2 and consider aromatase inhibitor.
2x 2 compounds share the teratogenic safety flag (CJC-1295 (without DAC), LGD-4033). Monitor accordingly.

Frequently Asked Questions

Can I take CJC-1295 (without DAC) with LGD-4033?

Yes, but with caution. Both CJC-1295 (without DAC) and LGD-4033 can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. Regular monitoring is advised.

Is CJC-1295 (without DAC) and LGD-4033 safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, estrogenic, teratogenic. Monitor accordingly.

What are the interactions between CJC-1295 (without DAC) and LGD-4033?

Both CJC-1295 (without DAC) and LGD-4033 can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time CJC-1295 (without DAC) and LGD-4033?

CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: CJC-1295 (without DAC) vs LGD-4033

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.